HOME >> BIOLOGY >> NEWS
Reducing allergens in the home helps inner-city children with asthma

vironmental Health Sciences.

Children who participated in the intervention had 21 fewer days of symptoms than the control group in the first year and an average of 16 fewer days during the second, follow-up year.

"We wanted this to have a long-term impact, not just for the duration of the study," Dr. Gruchalla said. "In many cases, we taught them simple cleaning measures to decrease the roach population things like not leaving food uncovered and caulking obvious cracks in the wall."

Interventions also included encasing the child's mattress, springs and pillow in allergen-impermeable covers; repairing water leaks; and removing carpet from the bedroom, if possible. Families were also given HEPA (high efficiency particulate air) filters. Cockroach extermination visits were provided in homes where children were sensitive to that allergen. The suggestions were typically well-received, Dr. Gruchalla said.

Study participants had suffered at least one asthma-related hospitalization or two asthma-related unscheduled doctor visits the six months prior to enrollment in the study. They also had a positive allergy skin test to at least one of 11 indoor allergens such as dust mites, molds, cockroaches, pets or rodents.

Researchers performed a baseline clinical evaluation, including questionnaires on asthma symptoms, medication use and the home environment. Later, researchers made a baseline home evaluation by visually inspecting and collecting dust from the child's bedroom. The families were then taught how to reduce allergens in their homes, told why it was necessary and given the needed tools to accomplish the task. Researchers followed up by phone and collected information about the child's asthma every few months during the intervention year and one year after.


'"/>

Contact: Staishy Bostick Siem
staishy.siem@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
8-Sep-2004


Page: 1 2

Related biology news :

1. Reducing the risk of frost damage to short-season crops
2. Reducing primary chemical emissions does not always reduce pollution
3. Reducing sodium leads to substantial drop in blood pressure, finds NHLBI study
4. Reducing methane emissions could lower overall abatement costs
5. Reducing VOC: new polymer coating process combines high degree of flexibility with improved environmental properties
6. Discovery By Fertility Specialist Offers Promise Of Reducing Multiple BirthsTied To Fertility Treatment
7. New Chemical Processing Technique Being Studied At UW May Hold Key To CleaningUp Hanford, Reducing Industrial Waste
8. National study shows dog and cat allergens are universally present in U.S. homes
9. FSU scientists develop new tests to detect nut allergens in processed food
10. Antibiotics alter GI tract microbes and increase lung sensitivity to allergens
11. Atacama rover helps NASA learn to search for life on Mars

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reducing allergens the home helps inner city children with asthma

(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: